23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Megakaryopoiesis is an original and complex cell process which leads to the formation of platelets. The homeostatic production of platelets is mainly regulated and controlled by thrombopoietin (TPO) and the TPO receptor (MPL)/JAK2 axis. Therefore, any hereditary or acquired abnormality affecting this signaling axis can result in thrombocytosis or thrombocytopenia. Thrombocytosis can be due to genetic alterations that affect either the intrinsic MPL signaling through gain-of-function (GOF) activity ( MPL, JAK2, CALR) and loss-of-function (LOF) activity of negative regulators ( CBL, LNK) or the extrinsic MPL signaling by THPO GOF mutations leading to increased TPO synthesis. Alternatively, thrombocytosis may paradoxically result from mutations of MPL leading to an abnormal MPL trafficking, inducing increased TPO levels by alteration of its clearance. In contrast, thrombocytopenia can also result from LOF THPO or MPL mutations, which cause a complete defect in MPL trafficking to the cell membrane, impaired MPL signaling or stability, defects in the TPO/MPL interaction, or an absence of TPO production.

          Related collections

          Most cited references86

          • Record: found
          • Abstract: found
          • Article: not found

          The lung is a site of platelet biogenesis and a reservoir for hematopoietic progenitors

          Platelets are critical for hemostasis, thrombosis, and inflammatory responses 1,2 , yet the events leading to mature platelet production remain incompletely understood 3 . The bone marrow (BM) is proposed to be a major site of platelet production although indirect evidence points towards a potential pulmonary contribution to platelet biogenesis 4-7 . By directly imaging the lung microcirculation in mice 8 , we discovered that a large number of megakaryocytes (MKs) circulate through the lungs where they dynamically release platelets. MKs releasing platelets in the lung are of extrapulmonary origin, such as the BM, where we observed large MKs migrating out of the BM space. The lung contribution to platelet biogenesis is substantial with approximately 50% of total platelet production or 10 million platelets per hour. Furthermore, we identified populations of mature and immature MKs along with hematopoietic progenitors that reside in the extravascular spaces of the lung. Under conditions of thrombocytopenia and relative stem cell deficiency in the BM 9 , these progenitors can migrate out of the lung, repopulate the BM, completely reconstitute blood platelet counts, and contribute to multiple hematopoietic lineages. These results position the lung as a primary site of terminal platelet production and an organ with considerable hematopoietic potential.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Distinct routes of lineage development reshape the human blood hierarchy across ontogeny.

            In a classical view of hematopoiesis, the various blood cell lineages arise via a hierarchical scheme starting with multipotent stem cells that become increasingly restricted in their differentiation potential through oligopotent and then unipotent progenitors. We developed a cell-sorting scheme to resolve myeloid (My), erythroid (Er), and megakaryocytic (Mk) fates from single CD34(+) cells and then mapped the progenitor hierarchy across human development. Fetal liver contained large numbers of distinct oligopotent progenitors with intermingled My, Er, and Mk fates. However, few oligopotent progenitor intermediates were present in the adult bone marrow. Instead, only two progenitor classes predominate, multipotent and unipotent, with Er-Mk lineages emerging from multipotent cells. The developmental shift to an adult "two-tier" hierarchy challenges current dogma and provides a revised framework to understand normal and disease states of human hematopoiesis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum.

              Calreticulin is an ER (endoplasmic reticulum) luminal Ca2+-buffering chaperone. The protein is involved in regulation of intracellular Ca2+ homoeostasis and ER Ca2+ capacity. The protein impacts on store-operated Ca2+ influx and influences Ca2+-dependent transcriptional pathways during embryonic development. Calreticulin is also involved in the folding of newly synthesized proteins and glycoproteins and, together with calnexin (an integral ER membrane chaperone similar to calreticulin) and ERp57 [ER protein of 57 kDa; a PDI (protein disulfide-isomerase)-like ER-resident protein], constitutes the 'calreticulin/calnexin cycle' that is responsible for folding and quality control of newly synthesized glycoproteins. In recent years, calreticulin has been implicated to play a role in many biological systems, including functions inside and outside the ER, indicating that the protein is a multi-process molecule. Regulation of Ca2+ homoeostasis and ER Ca2+ buffering by calreticulin might be the key to explain its multi-process property.
                Bookmark

                Author and article information

                Contributors
                URI : http://frontiersin.org/people/u/174641
                URI : http://frontiersin.org/people/u/461408
                URI : http://frontiersin.org/people/u/460077
                URI : http://frontiersin.org/people/u/466976
                URI : http://frontiersin.org/people/u/474047
                Journal
                Front Endocrinol (Lausanne)
                Front Endocrinol (Lausanne)
                Front. Endocrinol.
                Frontiers in Endocrinology
                Frontiers Media S.A.
                1664-2392
                12 September 2017
                2017
                : 8
                : 234
                Affiliations
                [1] 1INSERM UMR 1170, Gustave Roussy , Villejuif, France
                [2] 2Université Paris-Saclay, UMR1170, Gustave Roussy , Villejuif, France
                [3] 3Gustave Roussy, UMR1170 , Villejuif, France
                [4] 4Department of Genetics, AP-HP Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, UPMC Univ Paris 06 , Paris, France
                [5] 5Université Paris-Diderot , Paris, France
                Author notes

                Edited by: Pierre De Meyts, de Duve Institute, Belgium

                Reviewed by: Jean-Baptiste Demoulin, Catholic University of Louvain, Belgium; James M. Murphy, Walter and Eliza Hall Institute of Medical Research, Australia

                *Correspondence: William Vainchenker, verpre@ 123456igr.fr

                Specialty section: This article was submitted to Molecular and Structural Endocrinology, a section of the journal Frontiers in Endocrinology

                Article
                10.3389/fendo.2017.00234
                5600916
                28955303
                4ee29500-be67-4ab5-8e0e-9885a05d407d
                Copyright © 2017 Plo, Bellanné-Chantelot, Mosca, Mazzi, Marty and Vainchenker.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 30 June 2017
                : 28 August 2017
                Page count
                Figures: 2, Tables: 1, Equations: 0, References: 102, Pages: 10, Words: 7968
                Funding
                Funded by: Association Laurette Fugain 10.13039/501100006332
                Funded by: GIS-Institut des Maladies Rares 10.13039/501100006587
                Award ID: AO9102LS
                Categories
                Endocrinology
                Review

                Endocrinology & Diabetes
                thrombopoietin,mpl,jak2,mplr102p,thrombocytosis,thrombocytopenia
                Endocrinology & Diabetes
                thrombopoietin, mpl, jak2, mplr102p, thrombocytosis, thrombocytopenia

                Comments

                Comment on this article